Portfolio company
Ribonaut Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Ribonaut Therapeutics develops small molecule drugs that target and degrade disease-causing RNA to treat neurological conditions and movement disorders for human patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Ribometrix
The company develops small molecule therapeutics targeting RNA structures to treat human diseases for pharmaceutical partners and patients with cancer or neurodegenerative conditions.
Crucible Therapeutics
This biotechnology company develops RNA-based therapies for patients with neurodegenerative conditions such as amyotrophic lateral sclerosis and frontotemporal dementia.
Yumanity Therapeutics
This company develops small molecule drugs to treat neurodegenerative diseases for patients with conditions such as Parkinson's disease and amyotrophic lateral sclerosis.
Shape Therapeutics
The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.
Revona Bio
The company develops an RNA-targeted drug discovery platform to identify small-molecule compounds for pharmaceutical partners and biotechnology firms.
Biorchestra
The company develops RNA-based medicines and delivery systems for patients with neurodegenerative and rare central nervous system diseases.
Scripta Therapeutics
The company develops therapeutics that modulate transcription factor activity to treat neurodegenerative diseases for patients with conditions such as Alzheimer's and Parkinson's.
Typewriter Therapeutics
The company develops RNA-based genetic medicines for patients with cancer, autoimmune conditions and rare genetic diseases.